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 INTRODUCTION 
 The last three decades had witnessed the emergence of   HIV   
infection  as a  global pandemic affecting approximately 42 million 
people worldwide1. Since its first recognition in 1983, the disease has 
been reported virtually from all corners of globe, spreading at a  
tremendous pace and this trend is gathering momentum despite various 
multifaceted containment strategies by health organizations. A report by 
Joint United Nations Program on HIV /AIDS in 2003 estimated that 5 
million new cases are reported each year. 95 % reported cases occur in 
developing countries, with two- thirds of the cases from  sub-Saharan 
Africa alone. In India alone it has been estimated that 5.1 million people  
are living with  this illness.  Today,   AIDS alone account for a tragic 
death toll of 3 million deaths per year, making it the fourth leading cause 
of mortality worldwide1. 
 HIV infection affects entire   organ systems within the body.   Both 
HIV – 1 and  HIV – 2 belong to the family Retroviridae and the 
subfamily of lentiviruses. The infection is transmitted via various portals , 
sexual transmission  either heterosexual or homosexual being the major 
route of transmission. Transmission via percutaneous needle exposure  in  
intravenous drug abusers and health care personals is also on the rise. The 
virus gain entry into the host cell by attachment to the cellular receptor  
 CD4  molecule expressed  on the surfaces of helper T-cells, monocytes / 
macrophages  and  dendritic /  langerhans  cells.   
 
 
 
Diagram of HIV mode of infection and multiplication of HIV: 
 
 
 
 
 
 
 With in the host cell the viral RNA is converted into  
complementary DNA (c-DNA) by  reverse transcriptase enzyme. The  c-
DNA  gets incorporated  into  the host cell chromosomes. The integrated 
DNA is transcribed into messenger RNA (mRNA)  and the viral proteins  
are synthesized within the host cell.  These newly synthesized RNA and 
viral proteins are packaged together and released by the “budding 
process”. 
 Average time period elapsed  between  infection and onset of  
AIDS is approximately 8- 10 years. Between  this period the disease 
progress through a seroconversion  and  an asymptomatic  phase  of  
illness to primary generalized lymphadenopathy  and a gamut of 
secondary infections and  malignancies. 
Table 1 : 1993 revised classification system for HIV infection and 
expanded AIDS surveillance case definition for adolescents and adults. 
Classification 
CLINICAL  CONDITIONS 
A B C 
 
CD4 cell 
count 
(per micro 
liter) 
 
 
Asymptomatic
acute primary
infection or 
PGL 
Symptomatic
but not A or 
C 
conditions 
 
AIDS 
indicator 
conditions 
> 500 A1 B1 C1 
200 - 499 A2 B2 C2 
< 200 A3 B3 C3 
 HIV infected  patients under  classifications – A3, B3, C1 , C2 , C3   
are  defined  as AIDS  cases. 
CD4  count < 200/μl  is defined as AIDS regardless of presence of 
symptoms or opportunistic infections. 
1993 AIDS surveillance case definition CDC  Atlanta: 
Category A: 
One  or  more of  the following  in an  adolescent  ( > 13 years of age )  or 
adults as given in table 2: 
Category B: 
Consists  of  symptomatic  conditions  in  an  HIV  infected  
adolescent  or  adult   that  are  not   included  in  clinical  category  C  
and  that  meets  at least  one of the  following  criteria. 
a) The  conditions  are  attributed  to  HIV  infection  or  indicative  of  
a  defect  in  cell  mediated  immunity ( CMI) 
b) Conditions  are  considered by  physician  to have  a  clinical  
course  or require  management  that  is complicated by HIV  
infection 
 
Category C: AIDS  indicator conditions 
 
 Table 2: 1993 AIDS surveillance case definition CDC Atlanta 
Category A 
1 or more of  the 
following  : 
Category B: 
Category C: 
(AIDS  indicator conditions) 
i) Asymptomatic  
HIV  infection 
 
ii) Progressive  
Generalized  
Lymphadenopathy 
 
iii) Acute  primary  
HIV infection    
(history of  acute  
HIV  infection) 
1.Bacillary  
angiomatosis 
 
2.vulvo vaginal 
candidiasis , oral 
candidiasis 
 
3.cervical  
dysplasia , cervical 
carcinoma  in situ 
 
4.constitutional  
symptoms > 1 
month 
 
5.oral hairy  
leukoplakia 
 
6.herpes zoster - 2  
distinct episodes or  
more  than  one 
dermatome 
 
7.idiopathic  
thrombocytopenic  
purpura 
 
8.listeriosis 
 
9.pelvic  
inflammatory  
disease 
 
10.peripheral 
neuropathy 
1.Candidiasis of the  bronchi , 
trachea or  lungs 
 
2.esophageal   candidiasis 
 
3.cervical cancer – invasive 
 
4.coccidiomycosis – disseminated  
or  extra pulmonary 
 
5.cryptococcosis -  extra pulmonary 
 
6.cryptosporidiosis – chronic  
intestinal ( > one month  duration) 
 
7.cytomegalovirus disease ( other 
than lung , spleen  and  nodes) 
 
8.CMV retinitis   
 
9.HIV related  encephalopathy 
 
10.herpes simplex – chronic ulcer , 
bronchitis, pneumonia  or  
esophagitis 
 
11.histoplasmosis – disseminated  
or  extra pulmonary 
 
12. isosporiasis – chronic intestinal  
 
13.kaposi ’s sarcoma 
 
14.Burkett ’s lymphoma 
 
15.immunoblastic  lymphoma 
 
16.primary brain lymphoma 
  
 
  17.MAIC, M. kansasi infection  
- (disseminated  or  extra 
pulmonary) 
 
18.M . tuberculosis – any site 
 
19.mycobacterium other  
species or   unidentified  
species -- (disseminated  or  
extra pulmonary) 
 
20.pneumocystis  jiroveci  
pneumonia 
 
21.recurrent pneumonia 
 
22.progressive multifocal 
leukoencephalopathy 
 
23.salmonella  septicemia  -  
recurrent 
 
24.toxoplasmosis of brain 
 
25.wasting  syndrome 
 
From the beginning of the epidemic it was recognized that the 
cardiovascular system could also be involved by the virus, but until 
recently this aspect was not adequately emphasized.   Till late 1990s 
opportunistic infections and lymphoreticular malignancies were the 
principal mortality deciding factors in AIDS. With the advent of HAART 
there was a change in this scenario with dramatic improvement in life 
expectancy of HIV infected patients. As the survival was prolonged, long 
 term follow up of these patients revealed significant involvement of 
cardiovascular system both by the virus and as an adverse effect of 
HAART therapy2- 7 contributing for morbidity and mortality in them. 
Hence it is contemplated that strategies focusing on early detection of 
these cardiovascular   involvement in HIV patients should be an integral 
part of   the comprehensive management of AIDS patients. Currently the 
main diagnostic tool available that can be utilized is echocardiography, 
which may warrant the need for specialized   practitioners to be involved 
in management of every single case. Since this is difficult and cost-
ineffective, the  identification   of  a  molecular  biomarker  correlating 
with cardiovascular involvement would be a  novel  effort.  
Hitherto, available markers for monitoring HIV progression are 
CD4 T cell counts and HIV-RNA levels. But studies have revealed that 
they do not correlate with many forms of cardiac involvement including 
pericardial    effusion  and pulmonary hypertension.2-7,22 Similarly no 
available cardiac biomarkers like CK-MB, troponins- T and I, myoglobin 
etc have been found to be elevated uniformly irrespective of the form of 
cardiac involvement. Recently Brain natriuretic peptide (BNP) has been 
found to correlate inversely with left ventricular ejection fraction and is 
now employed in some centers for distinction of congestive 
cardiomyopathy from other causes of dyspnoea8. But large scale studies 
 comparing its utility in HIV patients and in other forms of cardiac 
pathologies are still lacking. 
 Cardiac isoform of alpha-2-macroglobulin (CA2M) is a novel 
molecular marker that has been confirmed by a couple of  recent studies 
to be such a marker 9-16 , the levels of which significantly raises during 
any form of cardiac illness irrespective of the nature of primary 
pathology. Hence the present study has been undertaken to explore  the 
possibility of utilizing CA2M as a marker for cardiac involvement in HIV 
patients. 
 
  
Aims & Objectives of the study 
 
 
 
 
i. To estimate the levels of CA2M in HIV infected patients with and 
without cardiac involvement as detected on echocardiography . 
 
ii. To assess the correlation of CA2M levels with cardiac involvement 
 
 Review  of literature 
HIV and  cardiovascular involvement 
 
The 2- to 5-year incidence of symptomatic HIV-related heart 
failure  ranges from 4 to 28 percent suggesting  a prevalence of 4 to 5 
million cases worldwide. Among HIV infected children upto 10 years of 
age 25% die with chronic heart disease2-5.   In a large autopsy series 
conducted  by Barbero et al 18 in  440 patients cardiac  involvement  in  
HIV  was documented  in  18.6 % cases .  The clinical  implication of  
this  remains  still under  evaluation, though several studies have 
concluded cardiac involvement to be an independent  prognostic factor in 
morbidity and mortality . The exact  mechanism by which HIV  can  
infect CD4+  receptor  negative cardiac myocytes  still remains unclear  
but  it has  been postulated based on autopsy studies18 that  HIV can  
cause cardiac damage  both by direct myocyte interaction  mediated by 
reservoir cells (eg. dendritic cells) and  indirect toxicity resulting from 
activation of multifunctional cytokines that contribute to progressive and 
late tissue damage.  The major cardiovascular  disorders  documented  in  
AIDS  patients  include  left ventricular   systolic  dysfunction and  
congestive  heart  failure resulting  from dilated cardiomyopathy ,   
isolated right  ventricular dysfunction , pericardial  effusion, myocarditis,  
primary  pulmonary  hypertension, malignancies and accelerated 
 atherosclerosis 2-7,18-21 .  In an echocardiographic analysis of 127 HIV 
patients, Cecchi et al.,4  demonstrated that 92 patients had evidence of 
cardiac involvement with a high incidence of pericardial effusion (29%) 
and dilated cardiomyopathy (26%).   
 
Dilated cardiomyopathy and Left  ventricular systolic dysfunction 
 
A 4 year  observational  study  of 296 patients  with HIV  infection 
by Currie PF et al.,  revealed  that 15%  have  dilated  cardiomyopathy,  
13 % isolated  right  ventricular  dysfunction  and  12 % with  borderline 
left ventricular dysfunction5 . Postulated  mechanisms  for HIV – 
mediated  cardiomyopathy  are18-21  : 
1. Direct cardiotoxicity of HIV virus 
2. Opportunistic infections 
3. Autoimmune response to viral  infection 
4. Cytokine alteration 
5. Nutritional deficiencies- selenium 
6. Drug toxicity 
Though exact mechanism remains elusive majority consider it to be 
result of postmyocarditis cardiomyopathy. Idiopathic lymphocytic 
myocarditis is a common postmortem finding in patients with ventricular 
dysfunction The overexpression of cytokines TNF-α , IL s and inducible 
nitric oxide synthase (INOS) evident in endomyocardial biopsies  appears 
 to be equally responsible . Occurrence of cardiomyopathy in children , in 
whom a disease unrelated to HIV infection would be rare , suggests a 
direct relationship between HIV disease and cardiomyopathy3.   Presence  
of cardiomyopathy correlate with low CD4+ counts and is a grave 
prognostic sign18-21. 
 
Pericardial effusion 
 
 Pericarditis and pericardial effusion constitute most common 
recognized cardiac involvement in HIV infection. In a review of  15  
autopsy and    echocardiographic  series  involving  1139 patients with 
HIV disease, Heidenreich et al. observed that, incidence  of  pericardial  
disease was 21%22.  Factors causing pericardial effusion  include  
opportunistic infections , most common  being   mycobacterium  
tuberculosis  or  MAI  infection ,  direct  viral  toxicity  and malignancies 
– Kaposi’s sarcoma and lymphoma. It  may be  part  of a  generalized 
capillary leak  syndrome  due  to  over  production  of inflammatory  
cytokines 23. Others are uremia and drug toxicity .  Occurrence of 
pericardial effusion is independent of CD4+ count6 and  is a grim  
prognostic sign with 6 month survival rate of merely 36%22, thus 
denoting an end-stage  disease.   
 Pulmonary hypertension 
 In 2 independent analysis of hospitalized AIDS patients Seonin et 
al. and Saidi et al.  observed that, primary pulmonary hypertension occur 
in about 0.5% of 24,25.  Lung histology frequently demonstrates 
plexogenic arteriopathy as in other cases of primary pulmonary 
hypertension.  It is often considered to develop secondary to recurrent 
lung infections, venous thromboembolism, or left ventricular dysfunction, 
but its occurrence in HIV-infected patients without documentation of 
prior history of any of these risk factors indicate some hitherto elusive 
mechanisms also contribute.  Hypothesized factors are cytokine related 
stimulation and proliferation of endothelium and smooth muscle 
hyperplasia due to receptor mediated action of viral proteins23-27.  In a 
review of 88 reported cases of pulmonary hypertension in AIDS patients 
Mesa et al. found no correlation of pulmonary hypertension with CD4+ 
count27. 
 
Ventricular diastolic dysfunction 
 Left ventricular diastolic dysfunction accompanied by left 
ventricular hypertrophy is more pronounced in AIDS patients27-30. 
Nishimura et al reported presence of left ventricular diastolic dysfunction 
in 53.8% of 40 asymptomatic   AIDS patients with a normal ejection 
fraction31. Left ventricular wall thickness and mass index tend to be 
 increased among AIDS patients compared to normal subjects. The 
pathogenesis of diastolic dysfunction is not clearly defined. Possible 
etiologies include direct infection of heart by HIV virus and opportunistic 
infections (myc. avium, cryptococcus neoformans, toxoplasma gondii) or 
direct involvement by a neoplastic process (kaposi sarcoma, lymphoma) 
and  infiltrative diseases (amyloidosis, tuberculosis). 
 
Infective endocarditis 
 
 Though intravenous drug abuse may be contributory to increased 
incidence of endocarditis,   incidence of endocarditis in HIV infected 
patients is comparable to that of   non-HIV infected individuals31. 
Common pathogens are Staphylococcus aureus and Salmonella . Fungal 
endocarditis is caused by Aspergillus fumigatus , Candida  and 
Cryptococcus neoformans and usually accompanies systemic fungemia. It  
will cause a rapid downhill deterioration in the  illness already 
compromised by cachexia and defective immunity .Besides infective 
causes 3-5% of AIDS patients ,mostly those with wasting syndrome 
develop marantic endocarditis 
 
Accelerated atherosclerosis and other vascular involvement 
 
 An increased risk for premature atherosclerotic diseases is noted in 
HIV patients on treatment with protease  inhibitors even in the absence of  
 other established risk factors like hypertension , diabetes mellitus etc.  
Insulin resistance and lipodystrophy are well known adverse  effects of 
therapy with protease  inhibitors32-34 This effect is due to impaired hepatic 
chylomicron uptake and endothelial triglyceride clearance coupled with 
increased apoptosis of adipocytes culminating in hyperlipidemia and 
insulin resistance. Abnormalities in lipid profile have also been noted 
with usage of  efavirenz. 
 
Besides this a wide range of inflammatory vascular   diseases  
including polyarteritis nodosa ,Henoch-Schonlein purpura and drug 
induced hypersensitivity  vasculitis may develop in HIV infected patients. 
Also HIV patients are at a higher risk for development of hypertension at 
a younger age than the general population due to HIV induced endothelial 
dysfunction, vasculitis and accelerated atherosclerosis impairing renal 
blood flow. 
 
Cardiovascular malignancy 
 
 Kaposi’s sarcoma and less frequently malignant lymphoma occur 
in AIDS patients27,35. Cardiac  involvement in Kaposi’s sarcoma indicate 
a disseminated disease. Cardiac Kaposi’s sarcoma is usually not 
obstructive or associated with clinical cardiac dysfunction, morbidity or 
mortality. Lymphomatous infiltration may be diffuse or may result in 
 discrete isolated lesions, which are usually derived from the Burkitt or 
immunoblastic type B cells . 
 Other abnormalities which have been detected include autonomic 
dysfunction, arrhythmias and isolated right ventricular dysfunction27. 
 
Current guidelines for workup 
 
 Currently only patients having symptoms and signs with regards to 
cardiovascular involvement such as shortness of breath, pericardial rub, 
S3 gallop or other signs of congestive failure are subjected to detailed 
evaluation with echocardiography in accordance with the previous 
concept that sub clinical cardiac illness do not influence the course of the 
illness6. 
Nevertheless, in light of the recent studies which strongly stress on 
focusing on cardiac involvement for better treatment outcome, this 
approach need to be modified so that timely detection of events can be 
done. Since frequent echocardiography by an expert may not prove cost -
effective a molecular biomarker which has a high sensitivity and 
specificity for  cardiac illness would be a novel one. 
A review of  the available molecular markers 
Currently  available markers for  cardiac  illness are  CK -MB, 
Troponin I / T ,  myoglobin and  BNP ( Brain Natriuretic Peptide ). 
 Though widely used each one has limitations and drawbacks. CK-MB, 
cardiac isoform of  creatine kinase  is the most widely used marker for 
diagnosing myocardial infarction . Though specificity is high, false 
positive results may be obtained in myopathies , renal failure , 
hypothyroidism etc . Similarly diagnostic value is limited only to cases of 
myocardial necrosis36-37 . The same applies to cardiac troponins as well, 
though their sensitivity in diagnosing minimal injuries to the heart is high 
compared to CK-MB . Myoglobin is useful only for diagnosis of 
myocardial infarction in the first one or two hours when other markers 
may not be elevated . BNP is a natriuretic peptide synthesized by 
ventricular myocardium in response to elevation in ventricular end 
diastolic pressure and volume . It has been approved by FDA as a 
diagnostic test for differentiating cardiac and respiratory causes acute 
dyspnea.  An elevated levels of BNP is diagnostic of acute left ventricular 
failure .It is also considered to be a prognostic marker for chronic heart 
failure and in acute coronary syndromes38-40.  Diagnostic utilities of BNP 
and its precursor form NT-pro BNP, which is more stable and has a better 
half life and serum  concentrations , are still under large scale trials so 
that a universal consensus  regarding its usage can be formulated . 
 Cardiac isoform of Alpha 2 Macroglobulin ( CA2M ) 
 Alpha 2 Macroglobulin (α2M), a plasma glycoprotein, is an acute   
phase reactant synthesized by liver .  In 1994, Rajamanickam et al, 
isolated a cardiac isoform of Alpha 2 Macroglobulin  (CA2M ) from  sera 
of aorta – constricted rats which was found to play a role in mediating 
cardiac hypertrophy(Genbank accession nos AY9196111 , AY921651 
and AY887133) . Biochemical characterizations found that this protein 
with a molecular weight 182 kDa is similar to α2M with respect to  
molecular weight and  biochemical properties. This had been postulated 
to  act as a molecular trigger signaling several molecular events 
associated with the induction of cardiac hypertrophy under pressure 
overloaded stress conditions9,10.This was confirmed by the observation 
that cDNA of 182 kDa serum protein, isolated from hypertrophied 
cardiac myocytes in aorta constricted animals,  induced hypertrophy upon 
direct injection in rat hearts12. The protein being synthesized in heart cells 
could have an autocrine or paracrine role in the development of cardiac 
hypertrophy9,10. The distinction between these two similar serum proteins, 
i.e., α2M and CA2M (182 kDa), is evident from the fact that the anti-
human α2M antibody did not cross-react with the 182 kDa protein 
whereas the anti-182 kDa protein antibody did cross-react with both rat 
and human α2M.Also, the isoelectric point of 182 kDa protein passes into 
 the value of α2M PI but with a lower number of protein spots (3 spots) 
than α2M (4 spots). In addition, purified α2M protein also failed to 
induce cardiac hypertrophy in experimental animals. Studies on the 
localization of 182 kDa protein induced during the development of 
cardiac hypertrophy showed that the 182 kDa protein was found in the 
cytosolic fraction obtained from the hypertrophy- induced heart by aortic 
constriction but not in the liver. 
Physiochemical properties 
 Biochemical characterizations suggest that the 182 kDa protein 
shares maximal homology with α2 macroglobulin (α2M) Both the 
proteins belong to the glycoprotein family.  The molecular weight of 
α2M is 725,000, as determined by ultracentrifugation, estimates of partial 
specific volume range between 0.72 and 0.735, and the isoelectric point 
5.0-5.2. α2M is a glycoprotein containing 8-10% carbohydrate (hexose 
4.25%, hexosamine 3.4%, fucose 0.2% and sialic acid 2.0%).The native 
α2M protein exist in two quite distinct forms: the electrophoretically 
“slow” S form, which is the circulating form that is reactive with 
proteinases; and the electrophoretically “fast” F form, which is produced 
irreversibly from the S form by reaction with proteinases or low-
molecular-weight amines. α2M consists of four identical subunits that are 
disulfide bonded in pairs, and the half-molecules thus formed are 
 associated noncovalently. The subunit contains a bond about two-thirds 
of the way from the N-terminus that tends to be cleaved spontaneously in 
denatured S-α2M, especially at elevated temperatures and alkaline pH41. 
α2M  receptor 
The low-density lipoprotein receptor-related protein (LRP) has 
been identified as a α2M receptor42. It is a 600-kDa endocytic membrane-
bound receptor belonging to the low-density lipoprotein family and is 
expressed in a broad spectrum of cell types as a 4525-amino acid residue 
single chain precursor. It is processed into a 85 kDa transmembrane β 
chain and  an approximately 515 kDa α chain  non-covalently associated 
with the extracellular part of the β chain. 
Reaction of α2M with proteinases causes a major conformational 
change in the protein that physically entraps the proteinase and also 
exposes the receptor recognition sites on each of the four identical 
subunits of the protein. The receptor-binding domain identifies only the 
activated α2M complexes and does not bind the native α2M43.  Binding 
to the multivalent LRP facilitates endocytosis of the ligand-receptor 
complex and clearance of α2M from the cell surface. Binding also elicits 
increases in intracellular inositol triphosphate, calcium, and cyclic AMP 
levels and also activates protein kinase C and phospholipase C -gamma 
and promotes alkalinization of cell cytoplasm44. Protein phosphorylation 
 is a fundamental mechanism whereby a variety of extracellular stimuli 
modulate cellular function. The serine-threonine kinase and protein 
kinase C (PKC) is strongly implicated in the cardiac hypertrophic 
response. It has also been shown that, the signaling pathways of stretch 
induced cardiac hypertrophy are mostly through the activation of PKC45.  
Both the aorta constricted as well as the 182 kDa protein (CA2M) 
injected rats showed up to a 3 fold induction of PKC activity within 10 
minutes of stress imposition. 
 Cardiac gene transfer has been previously achieved predominantly 
by direct injection into the myocardium or perfusion of an isolated 
coronary segment. Either of these approaches result in focal 
overexpression of the transgene and is therefore unlikely to modulate 
global cardiac function effectively.To overcome this problem the full-
length cDNA was cloned along with the signal peptide, thus rendering the 
182 kDa protein that is synthesized to be secretory so that the protein is 
released into the circulation and is able to exert its effect, binding to many 
growth modulating factors in the serum, and then targeted to 
cardiomyocytes by a receptor mediated mechanism10. The expressed 
protein of cDNA of 182 kDa is able to induce cardiac hypertrophy is 
evinced by the induced expression of the muscle specific marker genes 
namely β-MHC, MLC-2 and ANF characteristic of pressure overloaded 
 cardiac hypertrophy. Recent studies also clearly demonstrates and 
confirms the induction of β-MHC and the c-fos gene upon p182-
pcDNA3.1 (-) injection, characteristic of pressure overloaded cardiac 
hypertrophy12. 
Clinical utility of CA2M 
The prospective role  of CA2M as a molecular marker  for cardiac 
dysfunction in various forms of cardiac diseases has been analyzed in a 
couple of recent trials . Dr Ratinavel et al13 reported that levels of CA2M 
is significantly higher in patients having cardiac dysfunction resulting 
from various forms of cardiac illnesses including rheumatic heart disease, 
ischemic  heart disease and congenital heart diseases. In his study the 
serum levels  of CA2M was significantly high. (131+27.14mg/dl) when 
compared to values in non-cardiac   patients (47+5.2).  In another study  
Annapoorani et al14 demonstrated that CA2M level is elevated in post 
myocardial infarction in diabetic patients.  She concluded that CA2M 
levels could be used as a marker for retrospective identification of silent 
myocardial infection in diabetic patients.  It was also observed that values 
of CA2M in post-myocardial infarction patients without diabetes were 
also  elevated in parallel, stressing cardiac dysfunction specificity of this 
protein.   These studies elucidated the potential role of CA2M as a cardiac 
 biomarker which correlates with the cardiac involvement by various 
diseases  irrespective of primary pathologic process. 
 
 
 
 
 
 Materials and methods 
 
This study was conducted at Government Rajaji hospital, Madurai 
in collaboration with Department of Biochemistry, Madurai Kamaraj 
University . HIV infected patients involved in the study were selected 
from ART clinic, Government Rajaji Hospital . CA2M estimation in 
subjects and  controls using  ELISA and Western blot analysis were done  
at Laboratory, Department of Biochemistry, Madurai Kamaraj University. 
The study was approved by Ethical committee, Government Rajaji 
Hospital.  An informed consent was obtained from all study participants.  
Nature of Study :  Analytical Study,  
Sample Size  - 89 
Sample selection 
i. Inclusion criteria 
 69 HIV infected patients with symptoms suggestive of 
cardiovascular involvement in accordance to a standard questionnaire 
(see Appendix) were selected from ART clinic after preliminary  clinical 
assessment .Basic investigations were performed  before subjecting to  
detailed cardiovascular system evaluation by means of chest X-ray , 
Electrocardiography and Echocardiography .At the end of workup they 
 were divided into two groups – those with cardiovascular manifestations 
of HIV and those without. 
ii) Exclusion criteria 
Since the aim of the study is to analyze the usefulness of CA2M as 
an early marker for cardiovascular manifestations of HIV/AIDS , patients 
with clinical features of NYHA class III / IV cardiac failure and patients 
who had signs of congestive cardiac failure like S3 gallop, elevated JVP 
and lung basal crepitations were not included in the study. Similarly 
patients with known history of cardiac illnesses like ischemic heart 
disease, rheumatic heart disease, congenital heart disease  etc were not 
included . 
Patient categorization 
After  selecting the desired study population , each patient was 
subjected to clinical examination and subsequently investigations were 
done according to the proforma. Categorization into two groups was done 
based on evidence of cardiovascular involvement by echocardiography – 
Group A comprising of patients having echocardiographic findings and 
GroupB of patients who did not have any echocardiographic 
abnormalities. 
For comparison of results to a non-HIV infected  population , two 
groups of  age and sex matched  individuals ,each having 10 members – 
 Group C comprising of patients with various cardiac diseases (ischemic 
heart disease , rheumatic heart disease , congenital heart disease  ) and 
Group D comprising of normal individuals , were also included in the 
study . 
Echocardiography 
 M-mode ,2-D and Doppler echocardiographic studies were 
recorded for each patient. 
The abnormalities were defined as: 
1. Dilated cardiomyopathy – left ventricular dilatation and global 
systolic dysfunction Left ventricular ejection fraction is calculated 
by the formula : 
EF= (EDV-ESV)/EDV x 100 %   EDV- End diastolic volume, 
ESV- End systolic volume . 
Normal values of LVEF- 55- 75 % 
< 45% was considered abnormal. 
2. Diastolic dysfunction- 
Restrictive filling pattern of left ventricle  is determined by the 
ratio of early to late filling velocity by Doppler (E/A ratio) 
Normal mitral E/A ratio is – for adults<41 years 2.1±0.6 and for 
adults >55years 1.3 ± 0.3. Values above the limit are considered 
abnormal. 
 3. Pulmonary hypertension -  
Estimation of the pulmonary artery systolic pressure is derived 
using Bernoulli’s equation using tricuspid regurgitant jet .A fixed 
value of right atrial  pressure - 5 or 10 mmHg, was added to the 
transtricuspid pressure gradient to yield systolic right ventricular 
pressure (SRVP). 
In the absence of pulmonic stenosis SRVP is approximated to be 
systolic  pulmonary artery pressure (SPAP).  
Pulmonary hypertension is defined as SPAP > 30mm Hg at rest.   
Severe pulmonary hypertension is SPAP > 50mm Hg at rest. 
4. Mitral regurgitation – Severity is graded as: 
Grade I – jet (%LA) <15 and faint spectral doppler flow and 
ERO(effective regurgitant orifice) <0.2 cm2 
Grade II- ERO 0.2 to 0.29 cm2 
Grade III- ERO 0.3 to 0.39 cm2 
Grade IV- – jet (%LA) >50 and dense spectral doppler flow and  
ERO >0.40 cm2 
5. Aortic regurgitation – Severity is graded as: 
    Grade I- jet height(%LVOT) <25 , faint spectral doppler flow and 
     pressure half time (msec) >400  
    Grade II- jet height(%LVOT) 25-46  
          Grade III- jet height(%LVOT) 47-64 
Grade IV- jet height(%LVOT) >65, dense spectral doppler flow 
and Pressure half time (msec) <250 
6. Pericardial effusion- defined as an echo-free space surrounding 
heart. Quantified  as minimal ,mild ,moderate or large. 
Minimal – 5-20 ml fluid in pericardial cavity 
Mild- <5 mm in maximum dimension  
Moderate – 15-20mm in maximum dimension 
Large - >20 mm maximum dimension 
 
Collection of sera for CA2M estimation 
 The serum samples were collected in sterile EDTA coated tubes 
and within 5 hrs the samples were subjected to centrifugation for 15 min 
and then stored at -70º C until use. No samples were frozen/thawed more 
than twice. 
Raising CA2M antibodies in rats 
a) Pressure overload cardiac hypertrophy in Young Wistar albino  
rat was induced using aortic banding tantalum hemoclip 
b) Purification of 182-kDa protein:  The 182-kDa protein from the 
blood serum of aorta-constricted rats was purified by the method of 
Marriappan et al 9. Total serum proteins were subjected to gel 
 chromatography on a Affi-Gel blue column and eluted in DEAE-
Sepharose column .The eluted fractions from DEAE-Sepharose column 
containing the 182-kDa protein were pooled and fractionated in the 
BIOPAD HPLC system using a gel filtration column .The fraction 
containing the 182-kDa protein was collected and stored at  –70.C. 
c) Raising of anti-rat  182-kDa antisera 
Experimental rabbits were injected subcutaneously with 500 µg of 
HPLC purified 182-kDa protein along with Freund’s complete adjuvant. 
After 3 weeks, a booster injection of animals of about 200µg of 180 kDa 
protein with incomplete Freund’s adjutant was given. In the third week 
following the booster dose, the rabbit was bled by an intra cardiac 
puncture and serum was separated and further fractionated in ammonium 
sulphate [50% saturation] . The ammonium sulphate fractionation wais 
then   suspended in PBS, dialyzed against PBS for 12 hr and aliquots 
stored at –70ºC . 
Western blot analysis of patient’s sera with rabbit  anti-rat cardiac 
A2M sera: 
Immuno-cross reactivity between human sera and rabbit anti-rat 
CA2M sera was carried out by western blot analysis as detailed by 
Prabhakar and Rajamanickam . Briefly, 200mg of the total patients serum 
was fractionated on 10% SDS-polyacrylamide gel by electrophoresis . 
 The proteins were then transferred onto a nitrocellulose membrane. After  
transfer, treatment with antibody sera was carried out at 1:500 ratio at 
room temperature for 2h. Then a  second antibody treatment was done 
with a 1:1000 ratio horseradish peroxidase- [HRP] conjugated goat anti-
rabbit IgG at room temperature for 3h for labeling . The filter was washed 
and developed with 4- Chloronaphthol substrate solution [0.006% 4- 
Chloronaphtal, 0.0002% of 30% H2O2 at 20% methanol in PBS] 
 
Fig 1 : Western blot analysis of patient’s sera  
with rabbit  anti-rat CA2M antisera 
 CA2M measurements by Sandwich ELISA : 
CA2M levels serum in the sera of normal human and patients with 
cardiac and non-cardiac diseases were quantified by sandwich ELISA 
using anti-rat CA2M antibody raised in rabbit . The optimal concentration 
of antigens and antibody for coating was determined by checkerboard 
titration’s [BIORAD model 450 micro plate reader, Bio-Rad 
Laboratories, Hercules California, USA]. 
 
                                    
 
Fig 2 : Sandwich ELISA of CA2M antigen and  
anti-rat CA2M antibody 
 
 RESULTS 
 
Computer Analysis of Statistical data was done utilizing 
Epidemiological Information Package (EPI 2005) developed by World 
Health Organization. Frequencies, percentages, range, median, mean, 
S.D. and ‘p’ values were calculated using this package. 
 STATISTICS 
 
A. GENERAL CHARACTERISTICS 
Table 1:Age characteristics of study population 
Group A 
(HIV With 
Cardiac inv 
(Echo +ve) 
(n=31) 
Group B      
(HIVWithout
Cardiac inv)   
(ECHO-ve) 
(n=38) 
Group C 
(Cardiac 
without HIV)
Group D 
(Normal 
Healthy) 
Age 
Group 
No. % No. % No % No % 
<20 - - - - 1 10 1 10 
21-30 12 38.7 17 44.7 3 30 3 30 
31-40 14 45.2 19 50 2 20 6 60 
>40 5 16.1 2 5.3 4 40 - - 
Total 31 100 38 100 10 100 10 100 
Mean 33.1 yrs 31.7 yrs 35.7 yrs 32 yrs 
S.D. 6.2 5.7 10.3 7.1 
P 0.5365 
 
  Mean age of HIV population having cardiac involvement was 
33.1+6.2 years and for those who did not have was 31.7+5.7 years.  For 
the control group patients with cardiac diseases had a mean age of 
35.7+10.3 years and normal healthy population had a mean age of 32+7.1 
years. There is no statistically significant difference in the age 
composition between the study groups. 
  
Table 2: Sex composition of study groups 
Group A 
(HIV With 
Cardiac inv 
(Echo +ve) 
(n=31) 
Group B      
(HIVWithout
Cardiac inv)   
(ECHO-ve) 
(n=38) 
Group C 
(Cardiac 
without HIV)
Group D 
(Normal 
Healthy) Sex 
No. % No. % No % No % 
Male 19 61.3 20 52.6 6 60 6 60 
Female 12 38.7 18 47.4 4 40 4 40 
P 0.5577 
 
 
Statistically significant difference does not exist in the sex 
composition between the study groups.  All the groups were comparable 
with respect to sex distribution. 
  
Table 3: CA2M Levels (mg/dl) 
 
CA2M 
(mg/dl) 
Group A 
(HIV with 
Cardiac 
inv) 
Group  B 
(HIV 
without 
Cardiac inv)
Group C 
(Cardiac 
without HIV) 
Group D 
(Normal 
Healthy) 
Range 42.57-128.6 37.3-59.65 110.38-140.28 32.46-
42.18 
Median 97.42 43.68 125.29 36.68 
Mean 98.99 45.6 125.46 36.94 
S.D. 23.7 5.8 9.07 2.96 
P 0.0001 
 
¾ Normal healthy cases have lowest CA2M Values  
(36.94±2.96mg/dl) 
¾ HIV without cardiac involvement have lower CA2M Values 
(45.6±5.896mg/dl) 
¾ HIV with cardiac involvement have higher CA2M Values 
(98.99±23.7mg/dl) 
There  is statistically significant difference between HIV patients 
having cardiac involvement when compared to HIV patients without any 
cardiac involvement.  
 B. Characteristics of Group A and B (HIV population) 
Table 4 
Group A 
HIV 
with 
cardiac 
(Echo +ve) 
(n=31) 
Group B 
HIV 
without 
cardiac 
(Echo –ve) 
(n=38) 
 
 
Total (n-
69) 
 
 
VARIABLE 
No % No % No % 
 
 
P 
a) Sex 
Male 
Female 
 
19 
12 
 
61.3 
38.7 
 
20 
18 
 
52.6 
47.4 
 
39 
30 
 
56.5 
43.5 
 
0.6329 
( Not 
Significant)
b) ART 
Treatment 
ZLN 
SLN 
Nil 
 
 
15 
15 
1 
 
 
48.4 
48.4 
3.2 
 
 
20 
18 
- 
 
 
52.6 
47.4 
- 
 
 
35 
33 
1 
 
 
50.7 
47.8 
1.4 
 
 
0.9134 
(Not 
Significant)
c) Pulmonary TB 
+ ve 
- ve 
 
10 
21 
 
32.3 
67.7 
 
19 
19 
 
50 
50 
 
29 
40 
 
42 
58 
 
0.215(Not 
significant)
d)Pericardial 
Effusion 
10 32.4 - - 10 14.5 - 
 
e) Dilated 
Cardiomyopathy 
4 12.9 - - 4 5.8 - 
f) Pulmonary 
Hypertension 
15 48.5 - - 15 21.7 - 
g) Other forms 11 35.5 - - 11 15.9 - 
  
 In group A, echocardiography revealed the following data : 
 
Pericardial effusion- 14.5%, Dilated cardiomyopathy- 5.8%, Pulmonary 
Hypertension- 21.7%. 8 patients had more than one lesion.  Mitral valve 
prolapse was present in 4 patients, 2 patients had LV diastolic 
dysfunction and 2 patients had Aortic regurgitation.  
 
  
Table 5 
 
Group A 
HIV with 
cardiac 
(Echo +ve) 
(n=31) 
Group B 
HIV 
without 
cardiac 
(Echo –ve) 
(n=38) 
Total (n-69)  
VARIABLE 
Mean S.D Mean S.D Mean S.D 
P 
Age 33.1 6.2 31.7 5.7 32.3 5.9 0.3807 
Duration of 
illness 
2.58 1.72 2.33 1.92 2.44 1.82 0.3361 
CD4 count 110.5 63.3 138.8 47.3 126.12 56.42 0.0097 
CA2M  
Values 
98.99 23.73 45.62 5.77 69.6 31.33 0.0001 
significant
 
 C.RELATIONSHIP OF VARIOUS VARIABLES WITH CA2M 
LEVELS IN GROUPS A and B 
 
Table 6 
 
Age and CA2M Values 
Cases CA2M Values Age 
Group No. % Range 
Median
Mean S.D. 
<20 - - - - - - 
21-30 29 42 38.4-120.34 49.86 63.48 27.7 
31-40 33 47.8 37.3-128.01 51.46 69.52 31.4 
>40 7 10.1 40.46-128.6 97.42 95.31 36.57 
Total 69 100 37.3-128.6 51.46 69.6 31.3 
P 0.0752 
 
CA2M Values are not significantly affected by age. 
 Table 7 
Sex and CA2M Values 
Cases CA2M Values 
Sex 
No. % Range Median Mean S.D. 
Male 39 56.5 40.42-128.6 52.36 74.17 33.87 
Female 30 43.5 37.3-120.4 50.21 63.65 27.09 
P 0.181 
 
The CA2M Values are not significantly affected by sex. 
 Table 8 
CD4 Count and CA2M Values 
 
Cases CA2M Values 
CD4 Count 
No. % Range Median Mean S.D. 
Above  200/mm3 8 11.6 37.3-128.6 48.42 60.25 24.88
Below 200/mm3 61 88.4 39.3-106.02 51.46 70.82 32.05
P 0.3026 
 
CD4 < 200/ mm 3is defined as AIDS irrespective of symptoms and signs 
Though mean CA2M levels for CD4 Count <200 was 60.25+24.88 mg/dl 
and CD4 Count >200 was 70.82+32.05 mg/dl the difference was not 
statistically significant.  
 Table 9 
Duration of HIV Illness (in years) and CA2M Values 
 
Cases CA2M Values Duration 
of HIV 
Illness No. % Range Median Mean S.D. 
< 1 year 22 31.9 37.3-128.6 46.6 69.2 33.7 
1.1-3 yrs 33 47.8 38.4-128.49 50.4 63.8 27.6 
3.1-5 yrs 9 13 42.08-124.01 96.2 92.9 31.1 
> 5 yrs 5 7.2 40.31-126.21 54 67.6 34.7 
p 0.2996 
 
There is no statistically significant relation between duration of 
HIV Illness and CA2M Values.  But since duration of illness was defined 
since the time of detection of AIDS, the temporal association between 
disease progression and CA2M levels could not be conclusively 
commented by this single observation. 
 
 Table 10 
ART and CA2M Values 
 
Cases CA2M Values 
ART 
No. % Range Median Mean S.D. 
ZLN 35 50.7 37.3-128.6 52.36 69.48 32.32 
SLN 33 47.8 38.4-128.01 50.36 68.24 30.01 
Nil 1 1.4 118.24 118.24 118.24 - 
P 0.4392 
 
CA2M values are not significantly affected by type of ART 
treatment given.  As the study was not a prospective analysis, this single 
observation cannot be regarded as significant.  
 Table 11 
History of PT and CA2M Values 
 
Cases CA2M Values History 
of PT No. % Range Median Mean S.D. 
Positive 29 42 37.3- 50.36 65.7 29.22 
Negative 40 58 38.4- 56.1 72.42 32.85 
p 0.8601 
 
History of PT does not affect CA2M Values. 
 Table 12 
Pericardial effusion and CA2M Values 
 
Cases CA2M Values History 
of PE No. % Range Median Mean S.D. 
Present 10 14.5 92.38-128.01 122.18 114.73 14.7 
Absent 59 85.5 37.3-128.6 49.38 61.95 26.58 
p 0.0001 
 
Among cardiac cases with HIV, patients having pericardial 
effusion have higher CA2M values than those without. This difference is 
statistically significant. 
 
  
Table 13 
Dilated cardiomyopathy and CA2M Values 
 
Cases CA2M Values H/O 
DCM No. % Range Median Mean S.D. 
Yes 4 5.8 91.34-118.26 104.75 104.78 11.12 
No 65 94.2 37.3-128.6 50.24 67.43 30.91 
P 0.0352 
 
Presence of DCM significantly raises  CA2M Values. 
  
Table 14 
Pulmonary hypertension and CA2M Values 
 
Cases CA2M Values H/O 
PHT No. % Range Median Mean S.D. 
Yes 15 21.7 87.28-128.6 108.27 110.84 16.14 
No 54 78.3 37.3-127.02 64.28 58.14 23.99 
p 0.0001 
 
HIV patients having PHT have significantly higher CA2M values.  
         As depicted in Table 1 and Table 2 all the four study groups are 
comparable with respect to age and sex  .Similarly age and sex did not 
have any effect of  CA2M values (Table 6and 7). There is statistically 
significant difference ( p value <0.0001) between  CA2M values of HIV 
patients having cardiac involvement (Group A , mean CA2M levels 98.99 
mg/dl) and HIV  patients without cardiac involvement( Group B , mean 
CA2M levels 45.6 mg/dl). The mean CA2M levels for normal healthy 
controls ( Group D) was 36.94 mg/dl . Group C patients which comprised 
of patients with known cardiac illnesses had mean CA2M levels 
125.46mg/dl. This high levels are accounted by the fact that majority of 
them had significant LV dysfunction on echocardiography 
disproportionate to clinical symptoms which were ameliorated by 
treatment.   
The main HIV – associated cardiovascular abnormalities noted in 
this study were pericardial effusion, dilated cardiomyopathy and 
pulmonary hypertension. Two patients had left ventricular diastolic 
dysfunction. 4 patients had mitral valve prolapse, which though not 
related to HIV infection, was included as they had grade 1 to 2 MR. Two 
patients had grade 1 and 2 Aortic regurgitation respectively and they have 
also been included  , but HIV-related infective endocarditis as a cause  of 
aortic regurgitation was not proved by echocardiography. Among the 
 HIV-related complications pulmonary hypertension had the highest 
incidence (21.7%), followed by pericardial effusion (14.5 %) and dilated 
cardiomyopathy ( 5.8%). Eight patients had more than one lesion. Overall 
incidence of patients who were noted  to have cardiac involvement both 
HIV-related and non-related was 41.2% . Subgroup analysis showed that 
presence of pericardial effusion ,  dilated cardiomyopathy and pulmonary 
hypertension had a significant rise in CA2M levels (p value <0.001) 
illustrating the correlation of  CA2M levels with cardiovascular 
manifestations of AIDS. 
 DISCUSSION 
 
The dawn of 21st century has witnessed the emergence of  AIDS as 
the fourth leading cause of mortality worldwide1. Despite implementation 
of various awareness programs and containment strategies, the disease 
continues to spread at a tremendous pace and poses the biggest challenge 
the medical science faces today. With introduction of effective 
antiretroviral therapy, there was a significant change in the scenario as 
these therapies could improve the impaired host defense machinery.  This 
reduced the incidence of fatal opportunistic infections and substantially 
improved   the life expectancy of diseased. Follow up of these patients 
lead to the recognition of coexisting morbid pathologies involving 
multiple organ systems which were not adequately focused till then.  
Involvement of cardiovascular system, either direct or indirect in 
AIDS has now been contemplated to be a major factor contributing to 
significant morbidity and mortality in patients2-7.A wide spectrum of 
cardiac  manifestations has now been recognized in AIDS. Notable 
among them are pericardial effusion, dilated cardiomyopathy , pulmonary 
hypertension, accelerated atherosclerosis related to antiretroviral therapy, 
myocarditis, vasculitis and cardiac neoplasms2-7. Recent studies 
highlighted the impact of these in the course of illness and strongly 
recommended an active pursuit of these complications in patient workup . 
 Hitherto available markers like CD4 counts and HIV RNA levels do not 
correlate with many of these manifestations including pericardial 
effusion22 and pulmonary hypertension6,27. Techniques like 
echocardiography and angiography need involving specialized 
practitioners and is not a feasible  option as it is cost ineffective and not 
available in all settings.  
Currently available molecular markers including CK-MB, 
Troponin T/I  etc are specific for myocardial infarction and not useful in 
other forms of cardiac involvement. BNP is an established marker for 
cardiac failure but its clinical utility is confined to distinction of acute 
pulmonary edema from respiratory causes of acute dyspnoea. Hence the 
identification of a new marker, which is uniformly elevated in all forms 
of cardiac illnesses irrespective of the primary pathologic process, would 
be a novel one in detection of AIDS patients having cardiac involvement 
who can be further managed in concert with specialists.   
CA2M is a new molecular marker which may answer the search for 
a “universal” cardiac marker. It came to light first through the pioneer 
works by Rajamanickam et al9who isolated this molecule from the heart 
of experimental rats in which hypertrophy was induced by constriction of 
aorta. It was postulated that CA2M expression induce cardiac 
hypertrophy as its levels directly correlated with left ventricular mass 
 index10-11.This was confirmed when injection of purified cDNA of CA2M 
induced cardiac hypertrophy upon direct injection into the heart of 
experimental rats12. Also it was observed that in vivo administration of 
polyclonal antibody raised against CA2M  abolished cardiac hypertrophy 
by downregulating the expression of β-MHC and MLC-2 in experimental 
animals12.Since hypertrophy is the early adaptive response  of the failing 
myocardium , it was proposed that CA2M could be employed as a 
molecular marker , levels of which raises in cardiac dysfunction resulting 
from various pathologic processes. Its clinical utility was first tested by 
Dr Ratinavel (2005) et al 13who observed that the levels of CA2M are 
significantly elevated in cardiac dysfunction  resulting from different 
pathologies including ischemia , rheumatic heart disease , congenital 
heart disease etc irrespective of the primary pathology. Subsequent study 
by Annapoorni et al (2006)14established CA2M as a marker for detection 
of post myocardial infarction status in silent ischemia in diabetic 
individuals.  
The present study was conducted with an aim of early 
identification of cardiovascular involvement in HIV infected individuals. 
A total of 69 HIV who had NYHA class I and II dyspnoea and who did 
not have any prior history of any cardiac ailments were analyzed for 
cardiovascular system involvement by echocardiography and 
 electrocardiography.  Since the aim of the study was to analyze the 
usefulness of CA2M as an early marker for cardiac involvement in HIV, 
patients with clinical features of NYHA class III/IV cardiac failure and 
signs of failure like S3 gallop, elevated JVP and lung basal crepitations   
were not included in the study. The main cardiovascular abnormalities 
noted in this study were pericardial effusion, dilated cardiomyopathy , 
pulmonary hypertension and left ventricular diastolic dysfunction. 
Overall incidence of patients who were noted to have cardiac 
involvement both HIV-related and non-related was 41.2%. The non-HIV 
related cardiac manifestations included mitral valve prolapse with grade1-
2 mitral regurgitation  and mild aortic regurgitation. But they were also 
taken into account as their CA2M levels differed significantly from those 
without any cardiac involvement in echocardiography. The higher 
incidence of cardiac involvement in the study compared to other large 
scale clinical and autopsy studies may be owing to this and also due to 
cardiac symptom-based screening of HIV patients. 
Pericarditis  and  pericardial effusion  constitute  most common  
recognized   cardiac  involvement  in  HIV  infection 2-7,22.  In  a  review  
of   15 autopsy and echocardiographic  series  involving  1139  patients22 
with HIV  disease, incidence  of  pericardial  disease was 21%. Incidence 
of pericardial effusion in my study was 14.5 %. Factors causing  
 pericardial  effusion  include  opportunistic infections, most common 
being mycobacterium tuberculosis  or MAI infection , direct viral toxicity  
and  malignancies - Kaposi’s sarcoma and lymphoma.  It may a part of a  
generalized capillary leak syndrome 22,23 due  to overproduction of 
inflammatory cytokines. Others are uremia and drug toxicity. Occurrence 
of pericardial effusion is independent of CD4+ count and  is a grim 
prognostic sign22.  The cause of  pericardial effusion was  not  analyzed 
due  to  constraints  in  facilities for pericardial fluid analysis .Different 
grades of effusion ranging from mild effusion to severe  including one 
case of effusive constrictive pericardial effusion (CA2M level- 127.02 
mg/dl ) were observed. Mean values of CA2M levels for pericardial 
effusion was 114.73±14.7 (S.D) mg/dl (table 12) which is significantly 
higher compared to HIV infected patients without cardiac involvement 
(45.6±5.8 mg/dl)(table 3) and normal healthy individuals  (36.94±2.6 
mg/dl) (table 3). 
Ventricular dysfunction due to dilated cardiomyopathy is another 
important cardiac manifestation in HIV infection. A  4 year  observational  
study by  Currie PF et al. 296 patients  with HIV  infection revealed  15% 
have dilated cardiomyopathy, 13 % isolated  right  ventricular  
dysfunction  and  12 % with  borderline left ventricular dysfunction5. In 
the present study incidence of dilated  cardiomyopathy was 5.8% . All  
 patients had only mild to moderate LV dysfunction.  Postulated  
mechanisms  for HIV – mediated  cardiomyopathy  include direct 
cardiotoxicity of HIV virus, opportunistic infections, autoimmune 
response and nutritional deficiencies. Though exact mechanism remains 
elusive majority consider it to be result of postmyocarditis 
cardiomyopathy. Idiopathic lymphocytic myocarditis is a common 
postmortem finding in patients with ventricular dysfunction The 
overexpression of cytokines  TNF-α , IL s and inducible nitric oxide 
synthase  (INOS)  evident  in endomyocardial biopsies  appears to be 
equally responsible. Occurrence of cardiomyopathy in children , in whom 
a disease unrelated to HIV infection would be rare , suggests a direct 
relationship between HIV disease and cardiomyopathy.   Presence  of 
cardiomyopathy correlate with low CD4+ counts and is a grave 
prognostic mark 18-23.  Mean values of CA2M levels for dilated  
cardiomyopathy was 104.78 ± 11.12 mg/dl (table 13), significantly 
elevated compared to HIV patients without cardiac involvement  and  
normal healthy individuals. 
 2 independent analysis by Saeoane et al. and Saide et al.  in 
hospitalized  AIDS patients, primary pulmonary hypertension is 
estimated to occur in about  0.5% 24-27. In my study pulmonary 
hypertension had the highest incidence (21.7%) among the observed HIV 
- associated cardiac illnesses.  Majority had only mild pulmonary 
 hypertension . The difference between incidence in other studies in AIDS 
patients and this study group is noteworthy. Since large-scale studies in 
this area is lacking in Indian population influence of racial difference can 
not be attributed. Small size of the present study population is also a 
hindrance in assessing whether this was a mere coincidence or a 
significant difference. Further large-scale analysis is needed for 
clarification of this issue.  Lung histology frequently demonstrates 
plexogenic  arteriopathy  as  in  other  cases  of   primary  pulmonary 
hypertension. It is often considered to develop secondary to recurrent 
lung infections, venous thromboembolism or  left ventricular  dysfunction  
but  its  occurrence  in  HIV-infected  patients  without documentation  of  
prior  history of any  of  these risk  factors indicate some hitherto elusive  
mechanisms also contribute. Hypothesized factors are cytokine related 
stimulation and proliferation of endothelium and smooth  muscle  
hyperplasia due to receptor mediated action of  viral proteins.  In a review 
of 88 cases Mesa et al. found no correlation of pulmonary hypertension 
with CD4 count27.  Mean values of CA2M levels for pulmonary 
hypertension was 110.84±16.14 mg/dl (table 14), significantly elevated 
compared to HIV patients without cardiac involvement  and  normal 
healthy individuals. 
 To compare the results with the general population 10 patients with 
known cardiac illness including RHD, congenital heart disease and 
 ischemic heart disease and 10 normal individuals were also 
simultaneously analyzed.  Results were as follows : 
Group C - Patients with cardiac illnesses had a mean CA2M value  
125.46 +  9.07 mg / dl and Group D - Patients with cardiac illnesses had a  
mean CA2M Value 36.94 + 2.96 mg/dl.  These results are comparable 
with that of the study conducted by Dr.Ratanavel et. al.,14  (cardiac 
disease 131 + 27.14 mg/dl  and Normal 46 +  6 mg/dl ) who demonstrated 
a significant elevation of CA2M levels in patients with cardiac 
dysfunction resulting from various cardiac diseases.   
 Overall analysis of the data clearly indicates that CA2M levels rise 
significantly with all forms of cardiac involvement in HIV patients 
irrespective of the nature of the primary illness. This elucidates the role of 
CA2M as a molecular marker for cardiac involvement in HIV-infected 
patients . Since the study population comprised only of patients having 
mild to moderate symptoms and echocardiographic findings consistent 
with mild to moderate cardiac dysfunction it can be concluded that 
CA2M may be utilized for early detection of cardiac involvement in HIV-
infected patients. This may enable physicians in categorizing the HIV-
infected patients for effective management and also in prognosticating the 
disease as studies have highlighted the fact  that cardiac involvement 
correlates with a bad prognosis in the course of the illness2-5,18. 
  
Limitations of the study 
 
Since the study population was small large-scale studies may be 
required to explore the profound utility of this biomarker in clinical  
practice. Another hindrance at present is the high cost involved in the 
manufacturing of the antisera as this molecule is still in the experimental 
phase.  But if the efficacy is confirmed by large-scale analysis and a 
definite indication is formulated then this can be overcome by involving 
multinational biotechnology manufacturing sectors. As the study was a 
cross-sectional analysis with all tests done in one sitting, follow up of 
patients could not be performed. This disallowed from assessing the 
alterations of CA2M levels with HAART therapy. Hence a definite 
prognostic role besides that as a cardiac marker could not be established. 
Further follow up studies are warranted in this aspect.  Similarly due to 
non -availability of a protease inhibitor based HAART regimen therapy 
induced  lipid abnormalities and accelerated atherosclerotic diseases were 
not analyzed in this study.  
  
CONCLUSION 
 
1. CA2M levels are significantly elevated in HIV patients with 
cardiac involvement. 
2. CA2M can be utilized as an early molecular marker in HIV 
infected individuals for assessing cardiac involvement who do not 
have symptoms or signs of overt congestive cardiac failure.  
 
 SUMMARY 
 
 The present study was undertaken with an aim to establish the 
diagnostic utility of CA2M as an early biomarker for cardiac involvement 
in HIV infected individuals.  A total of 69 HIV infected patients with 
history suggestive of cardiac involvement were analyzed, after excluding 
patients with known history of other cardiac illnesses and patients with 
advanced symptoms. On echocardiographic evaluation 31 had cardiac 
involvement. Main abnormalities noted in my study were pulmonary 
hypertension, pericardial effusion, dilated cardiomyopathy and LV 
diastolic dysfunction.  For comparison of results with a general 
population 10 patients with known  cardiac diseases and 10 normal 
control individuals were also analyzed.   
 CA2M levels were found to be significantly elevated in HIV 
patients who had cardiac involvement and values were comparable to 
patients without HIV infection who had cardiac illnesses as noted in a 
previous study by Dr Ratinavel et al. This clearly illustrates the role of 
CA2M as an early biomarker for cardiac involvement in HIV.   Along 
side it was also observed that pulmonary hypertension had a higher 
incidence in the analyzed HIV-infected population which has not so far 
been reported in any other studies conducted to date.  
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 APPENDIX - II 
PRO FORMA 
CARDIAC ISOFORM OFALPHA-2-MACROGLOBULIN AS AN  
EARLY MARKER FOR CARDIAC INVOLVEMENT IN  
HIV/AIDS PATIENTS 
 
NAME:                                                AGE:                 SEX: 
IP No/ADDRESS:                                              OCCUPATION: 
SYMPTOMS: 
CVS:              h/o dyspnoea/orthopnoea/PND : 
                       h/o angina/angina equivalents   : 
                       h/o dependent edema                  : 
HIV related:  h/o weight loss                             : 
                       h/o  chronic fever/cough             : 
                       h/o  chronic diarrhoea               : 
                       h/o  skin manifestations              : 
                       others                                            : 
PAST HISTORY 
HT:                DM:             IHD:           POVD:   
STROKE/TIA   : 
H/O PULMONARY TUBERCULOSIS : 
 IF YES  H/O ATT INTAKE  : 
HIV STATUS 
DURATION OF ILLNESS   : 
CD4 COUNT AT DIAGNOSIS  : 
H/O OPPORTUNISTIC INFECTIONS : 
DURATION OF ANTIRETROVIRAL THERAPY: 
ART DRUGS TAKEN   : 
PERSONAL HISTORY 
SMOKING/TOBACCO :                             ALCOHOL: 
FAMILY HISTORY 
HT:            DM:            IHD: 
O/E:- 
PR-                      BP-                 CAROTIDS-                JVP- 
PERIPHERAL VASCULAR SYSTEM- 
CVS:-    
APICAL IMPULSE  SITE(ICS):                CHARACTER: 
 S1                  S2             S3                S4 
MURMUR-SYST/DAIST :                 AREA : 
E/O EFFUSION : 
RS:- 
 P/A:- 
CNS:- 
INVESTIGATIONS 
Hb(g%):                       TC(per mm3 ):                    DC(%):P    L     E   M 
RBS(mg/dl):                B Urea(mg/dl):              S Creat(mg/dl):  
S LIPID profile - 
T Cholesterol -                                  LDL -                    VLDL -    
HDL -      T Triglycerides-  
CD count: CD4 (per mm3 )-                     
                  CD8 (per mm3 )- 
                   CD4  / CD8  RATIO- 
HIV STATUS 
ELISA- 
WESTERN BLOT- 
CXR PA VIEW  
 
ECG- RATE              SR/NON SR                        P wave 
PR interval                      QRS                  ST-T segment-        
ECHO-            LVID(S)                 LVID(d)                      EF 
                         MV-                       AV-                 TV-             PV- 
                          PERICARDIAL EFFUSION- 
                         MV  E/A-                   LVOT- 
                         PULMONARY HYPERTENSION- 
 
CARDIAC ALPHA-2 MACROGLOBULIN  (CA2M) LEVELS- 
 APPENDIX - III 
ABBREVIATIONS 
ANF   - Atrial Natriuretic Factor  
ATP  - Adenosine tri phosphate 
BNP   - Brain natriuretic peptide 
cDNA - Complementary deoxyribonucleic acid  
dNTP  - Deoxynucleotide triphosphate  
DCM  - Dilated Cardiomyopathy 
EDTA - Ethylene diamine tetraacetic acid 
g, mg, µg, ng- gram, milligram, microgram, nanogram 
HPLC - High performance liquid chromatography  
IgG  - Immunoglobulin – G 
IL  - Interleukin 
INOS  - Inducible nitric oxide synthase  
MHC  - Myosin heavy chain 
MLC  - Myosin light chain 
mRNA - messenger ribonucleic acid 
PCR  - Polymerase chain reaction 
 PMSF - Phenyl methyl sulphonyl fluoride 
PKC   - Protein kinase C 
PHT  - Pulmonary Hypertension  
RHD  - Rheumatic Heart Disease 
TGF-β - Transforming growth factor – β  
TNF -α - Tumor Necrosis Factor - α 
    
  
Fig. 10a: Chest X-Ray showing pericardial effusion in a HIV patient 
 
 
 
Fig. 10b: 2-D Echo showing posterior echo-free space indicating  
pericardial effusion 
 
 
  
 
 
Fig. 11a:    M-mode Echo showing dilated ca   rdiomyopathy 
 
 
 
 
 
Fig. 11b :    Doppler Echo showing mitral regurgitation 
 
  
 
 
 
Fig. 3 AGE COMPOSITION OF STUDY POPULATION 
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Fig. 4  SEX COMPOSITION OF STUDY POPULATION  
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CA2M Levels (mg/dl) in various Groups  
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Fig 6 :  Pie chart of echocardiographic analysis of study  
groups A and B. 
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Fig. 7  PERICARDIAL EFFUSION AND CA2M VALUES 
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FIG. 8.  DILATED CARDIOMYOPATHY AND CA2M VALUES 
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FIG. 9 PULMONARY HYPERTENSION AND CA2M VALUES 
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FIG. 12.  CA2M LEVELS AND CARDIAC INVOLVEMENT 
COMPARISON TO STUDY BY Dr. RATINAVEL 
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APPENDIX IV - MASTER CHART 
 
HIV patients – Group A and B 
 
SL. 
NO AGE SEX 
CARDIAC 
SYMPTOM 
DURATION
(YEARS) 
CD4 
COUNT/mm3
ART 
(Y/N) 
H/O 
pulTB PE DCM PHT OTHERS 
CAZM 
(mg/dl) 
1 35 F Y 1.5 178 ZLN - - - - - 58.18 
2 42 M Y 1 30 SLN + - - +(Mod) - 97.42 
3 28 M Y 3 165 SLN + - - - - 49.86 
4 25 F Y 2 134 SLN + - - - - 59.65 
5 28 M Y 1 72 SLN + - 
+(Mild 
Lvdysf) - - 91.34 
6 32 M Y 1 70 SLN + 
+(eff 
constr) - - - 127.02 
7 37 M Y 3 45 ZLN - 
+ 
(modPE) - +(sev) - 128.01 
8 24 F Y 3.5 76 SLN - 
+(mild 
PE) - +(mild) - 108.21 
9 45 M Y 10 216 ZLN - - - - - 54.01 
10 31 M Y 1 90 ZLN - 
+(mild 
PE) - +(mild) - 96.86 
11 36 M Y 4 93 SLN + - - - Grade 2 Aortic Regurgitation 92.29 
12 22 M Y 1 203 SLN - - - - - 41.67 
13 22 F Y 2 174 ZLN - - - - 
Mitral valve prolapse / MR 
Grade 1 64.28 
14 28 F Y 3 228 ZLN - - - +(mild) Trivial mitral regurgitation 87.28 
15 33 F Y 2 143 ZLN + - - - - 59.45 
16 34 F Y 1.5 138 SLN + - - +(mild) - 89.16 
 SL. 
NO AGE SEX 
CARDIAC 
SYMPTOM 
DURATION
(YEARS) 
CD4 
COUNT/mm3
ART 
(Y/N) 
H/O 
pulTB PE DCM PHT OTHERS 
CAZM 
(mg/dl) 
17 36 M Y 2 152 SLN - - - - Trivial mitral regurgitation 42.57 
18 28 M Y 4 186 SLN - - - - - 42.4 
19 25 F Y 2 268 SLN - - - +(mild) - 106.02 
20 29 F Y 0.5 106 SLN + - - +(mild) 
Mitral valve prolapse Grade 2 
MR 118.24 
21 43 M Y 2 59 ZLN - - - +(mild) - 128.49 
22 30 F Y 1 60 ZLN - - - +(mod) - 108.27 
23 26 M Y 1 78 SLN - - - - - 43.56 
24 38 M Y 2 78 ZLN + - - - - 50.24 
25 33 M Y 3 128 SLN + - - - - 43.53 
26 30 F Y 3 100 SLN + - - - - 42.72 
27 35 M Y 1 142 ZLN - - - - - 46.81 
28 29 F Y 1 205 ZLN - - - - - 39.36 
29 21 F Y 2 176 SLN + - - - - 50.36 
30 32 F Y 8 155 SLN - - - - - 40.31 
31 24 F Y 2 98 SLN + - - - - 38.4 
32 28 F Y 1 90 ZLN - - - - - 42.9 
33 36 F Y 1 165 ZLN + - - - - 46.4 
34 33 F Y 1 175 ZLN - - - - - 37.3 
35 45 M Y 1 110 ZLN - - - +(mod)
Grade 2 Mitral  
Regurgitation 128.6 
36 34 M Y 1 112 SLN + - - - - 44.69 
37 28 M Y 1 95 ZLN - - - - - 40.6 
38 41 M Y 1 110 ZLN - - - - 
 LV diastolic 
 dysfunction 90.16 
39 29 F Y 1 50 ZLN - - - - - 43.8 
40 35 M Y 4 50 ZLN + 
+(mod 
PE) - +(mild) - 124.01 
41 37 M Y 2 160 SLN + - - - - 51.46 
42 28 F Y 3.5 102 SLN - - - - - 42.08 
 SL. 
NO AGE SEX 
CARDIAC 
SYMPTOM 
DURATION
(YEARS) 
CD4 
COUNT/mm3
ART 
(Y/N) 
H/O 
pulTB PE DCM PHT OTHERS 
CAZM 
(mg/dl) 
43 34 M Y 4 46 ZLN - - 
+Gr2LV 
sys dysf - - 118.26 
44 46 M Y 3 66 SLN + 
+(mild 
PE) - +(mild) - 128.01 
45 31 M Y 2 60 SLN + - - - - 46.24 
46 25 F Y 1.5 70 ZLN - - - - - 40.82 
47 35 M Y 2 95 SLN + - - - - 44.69 
48 29 M Y 1 105 ZLN - - - - - 42.08 
49 29 F Y 2 180 ZLN - - - - 
Mitral valve prolapse  
Grade 1 MR 50.06 
50 40 M Y 6 160 SLN + - - - - 46.48 
51 33 F Y 3 138 ZLN - - - - - 49.38 
52 38 M Y 2 152 ZLN + - - - - 52.36 
53 39 M Y 1 188 SLN + - - - - 40.42 
54 26 F Y 2 270 ZLN + - - - 
Mitral valve prolapse  
Grade 1 MR 68.38 
55 40 M Y 4 120 SLN - 
+(mild 
PE) - - - 92.38 
56 27 F Y 5 70 SLN - 
+(mod 
PE) - - - 120.34 
57 34 M Y 8 60 ZLN - 
+(mod 
PE) - +(mild) - 126.21 
58 39 M Y 2 105 ZLN + - - - - 48.82 
59 29 M Y 6 130 SLN - - - - Grade 1 AR 70.82 
60 34 M Y 3 140 ZLN - - 
+(LV 
sys dys) - - 102.68 
61 26 F Y 2 210 ZLN + - - - - 42.82 
62 29 F Y 1 170 ZLN - - - - - 48.24 
63 43 M Y 3 160 ZLN - - - - - 40.46 
64 30 F Y 2 100 SLN + - - - 
LV Grade 1 
 Diastolic dysfunction 72.46 
 SL. 
NO AGE SEX 
CARDIAC 
SYMPTOM 
DURATION
(YEARS) 
CD4 
COUNT/mm3
ART 
(Y/N) 
H/O 
pulTB PE DCM PHT OTHERS 
CAZM 
(mg/dl) 
65 36 M Y 2 92 ZLN -       - - +(mild) - 87.86 
66 28 F Y 4 48 SLN - 
+(mod 
PE) - - - 96.24 
67 33 F Y 2 98 ZLN + - - - - 38.42 
68 35 M Y 0.5 174 SLN - - 
+(LV 
sys dys) - - 106.82 
69 29 M Y 2 230 SLN - - - - - 42.42 
 
 
 
 
Cardiac patients without HIV – Group C 
 
SL 
NO AGE SEX 
CARDIAC 
DISEASE CA2M(mg/dl)
1 22 F RHD/MR/PHT/CCF 128.28 
2 30 F RHD/MS/MR/PHT/CCF 136.42 
3 46 M Bicuspid Aortic Valve / AS / AR 122.42 
4 47 M CAHD / A/C AWMI/ LVEF – 58% 128.16 
5 35 M Dilated Cardiomyopathy / CCF 140.28 
6 39 M 
Pericardial Effusion 
(Tuberculosis) 122.14 
7 20 F VSD / PHT 130.21 
8 28 M OS - ASD 110.38 
9 42 M CAHD / OLD IWMI/ LVEF - 60% 120.16 
10 48 F CAHD / OLD IWMI/ LVEF - 66% 116.14 
 
 Normal individuals –Group D 
 
SL 
NO AGE SEX 
NORMAL 
CONTROLS CA2M(mg/dl) 
1 22 M Normal Echo 40.38 
2 30 F Normal Echo 38.18 
3 35 M Normal Echo 34.12 
4 40 F Normal Echo 36.18 
5 28 M Normal Echo 38.21 
6 19 F Normal Echo 36.18 
7 40 M Normal Echo 34.28 
8 35 M Normal Echo 37.18 
9 36 M Normal Echo 32.46 
10 35 F Normal Echo 42.18 
 
 
